The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...
Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...
Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...
Averaging up to 20% of weight loss, adults taking Zepbound had 25 fewer breathing interruptions each hour as they slept.
The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...
The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...